Theravance Biopharma (NASDAQ:TBPH) Reaches New 1-Year High - Time to Buy?

Key Points

• Theravance Biopharma's share price reached a new 52-week high of $14.55 during trading, with a last known price of $14.21.
• Multiple analysts have upgraded the stock's rating to "strong-buy", with the average price target among analysts set at $23.00.
• Insiders own 6.90% of the stock, and recent transactions show significant activity, including a sale of 10,000 shares by a senior vice president.

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report)'s stock price reached a new 52-week high on Tuesday . The company traded as high as $14.55 and last traded at $14.21, with a volume of 172 shares changing hands. The stock had previously closed at $14.40.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Zacks Research downgraded Theravance Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Monday, September 15th. Wall Street Zen raised Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 16th. B. Riley began coverage on Theravance Biopharma in a research note on Friday, September 12th. They issued a "buy" rating and a $28.00 price objective for the company. BTIG Research upped their price objective on Theravance Biopharma from $24.00 to $25.00 and gave the company a "buy" rating in a research note on Friday, June 27th. Finally, Jones Trading upgraded Theravance Biopharma to a "strong-buy" rating and set a $24.00 price objective for the company in a research report on Tuesday, June 17th. Two investment analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the company has a consensus rating of "Buy" and an average target price of $23.00.

Theravance Biopharma Price Performance

The stock has a fifty day moving average price of $12.67 and a two-hundred day moving average price of $10.76. The company has a market cap of $699.00 million, a P/E ratio of 57.83 and a beta of 0.05.

Insider Activity

In other Theravance Biopharma news, SVP Rhonda Farnum sold 10,000 shares of the business's stock in a transaction on Monday, July 14th. The stock was sold at an average price of $11.39, for a total value of $113,900.00. Following the sale, the senior vice president directly owned 326,918 shares in the company, valued at $3,723,596.02. The trade was a 2.97% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 6.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Theravance Biopharma

Several hedge funds have recently made changes to their positions in TBPH. Nuveen LLC bought a new stake in Theravance Biopharma during the first quarter worth about $3,348,000. Jefferies Financial Group Inc. lifted its stake in Theravance Biopharma by 1,191.9% during the second quarter. Jefferies Financial Group Inc. now owns 276,887 shares of the biopharmaceutical company's stock worth $3,054,000 after purchasing an additional 255,455 shares during the last quarter. Acadian Asset Management LLC lifted its stake in Theravance Biopharma by 121,993.7% during the first quarter. Acadian Asset Management LLC now owns 174,594 shares of the biopharmaceutical company's stock worth $1,554,000 after purchasing an additional 174,451 shares during the last quarter. Qube Research & Technologies Ltd lifted its stake in Theravance Biopharma by 80.2% during the second quarter. Qube Research & Technologies Ltd now owns 205,280 shares of the biopharmaceutical company's stock worth $2,264,000 after purchasing an additional 91,341 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its stake in Theravance Biopharma by 30.8% during the second quarter. BNP Paribas Financial Markets now owns 387,472 shares of the biopharmaceutical company's stock worth $4,274,000 after purchasing an additional 91,300 shares during the last quarter. 99.10% of the stock is currently owned by hedge funds and other institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.